💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Zolpidem Tartrate

CHEMBL3989820 Phase 4 Zugelassen Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
764.9 g/mol
LogP
—
Phase
4

A tartrate salt form of zolpidem with the same therapeutic properties. This sedative-hypnotic medication is widely prescribed for short-term treatment of insomnia, helping people fall asleep more quickly and stay asleep longer.

Molekularmasse

764,9000 g/mol

TPSA

190,00 Ų

Therapeutische Bereiche

Pain Management Asthma Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Chronic Kidney Disease Obesity Hypertension Breast Cancer Chronic Pain Heart Failure

Wirkmechanismus

Selective GABA-A receptor alpha-1 subunit agonist.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Selective GABA-A receptor alpha-1 subunit agonist.

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.O=C(O)C(O)C(O)C(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/2C19H21N3O.C4H6O6/c2*1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19;5-1(3(7)8)2(6)4(9)10/h2*5-10,12H,11H2,1-4H3;1-2,5-6H,(H,7,8)(H,9,10)

                

                

                

                    
                    

                        
Molecular Formula

                        
C42H48N6O8

                    

                    
                    

                        
HBD / HBA

                        
4 / 10

                    

                    
                    

                        
Rotierbare Bindungen

                        
9

                    

                    
                    
                    

                        
Schwere Atome

                        
56

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
A tartrate salt form of zolpidem with the same therapeutic properties. This sedative-hypnotic medication is widely prescribed for short-term treatment of insomnia, helping people fall asleep more quickly and stay asleep longer.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective GABA-A receptor alpha-1 subunit agonist.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Zolpidem Tartrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3989820.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 441338.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.